Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Resources
PER Pulse™ Recapfor Cancer Summaries and Commentaries™: Update From Orlando: Advances in Myeloproliferative Neoplasms focuses on trials likely to be of interest to practicing hematologists, immediately or in the near future. Each recap provides a brief overview of trial data, along with a summary of experts' perspectives.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Cancer Summaries and Commentaries™: Update From Orlando: Advances in Myeloproliferative Neoplasms
Expiration Date: January 29, 2017
Media: Internet - based
Activity Overview
This activity is designed to update physicians on the data that have been recently presented in Orlando so that they can assess and prepare to apply these findings to their clinical practice to improve patient care.
CME Activity Table of Contents
-
Myeloproliferative Neoplasms
Discussed by Ruben Mesa, MD
-
Chronic Myeloid Leukemia
Discussed by Michael Mauro, MD
Instructions For This Activity & Receiving Credit
|
Target Audience
This educational activity is directed toward medical oncologists/hematologists and fellows who treat patients with myeloproliferative neoplasms. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of myeloproliferative neoplasms will be invited to participate.
Educational Objectives
At the conclusion of this activity, you should be better prepared to:
- Explain results from recently completed trials concerning the management of MPNs in the context of efficacy, safety, as well as prognostic and predictive markers
- Evaluate clinical trial data on novel strategies to manage MPNs
Faculty, Staff, and Planners' Disclosures
Faculty
Ruben Mesa, MD, FACP
Chair, Division of Hematology & Medical Oncology
Deputy Director, Mayo Clinic Cancer Center
Chair, Arizona Cancer Coalition
Professor of Medicine
Mayo Clinic Cancer Center
Scottsdale, Arizona
Disclosure: Grant/Research Support: Incyte, Gilead, CTI, Genentech, NS Pharma, Inc., Promedior Consultant: Novartis
Michael Mauro, MD
Hematologist
Leader, Myeloproliferative Neoplasms Program
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosure: Grant/Research Support: Novartis
The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC
Disclosure Policy and Resolution of Conflicts of Interest (COI)
It is the policy of PER® to ensure the fair balance, independence, objectivity, and scientific objectivity in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Hardware And Software Requirements
Supported BrowsersInternet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
- A PowerPC processor-based Macintosh computer
- At least 64MB of RAM
- Mac OS 7.5 or later
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
March 30, 2019
